{"groups":[{"description":"Patients receive cisplatin IV on days 1, 22, and 43 and undergo 3-dimensional conformal or intensity modulated radiotherapy once daily, 5 days per week, on days 1-47.","id":"FG000","title":"Arm A (Cisplatin and Radiotherapy)"},{"description":"Patients receive cisplatin and radiotherapy as in Arm A. Patients also receive erlotinib hydrochloride PO QD on days -7 to 47.","id":"FG001","title":"Arm B (Cisplatin, Radiotherapy, Erlotinib)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"105"},{"groupId":"FG001","numSubjects":"99"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"96"},{"groupId":"FG001","numSubjects":"95"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"4"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Patients were randomized between December 2006 and October 2011."}